Compile Data Set for Download or QSAR
maximum 50k data
Found 162 Enz. Inhib. hit(s) with all data for entry = 57
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221600(US9303045, 87 | US9695195, 87)
Affinity DataIC50:  0.180nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221544(US9303045, 30 | US9695195, 30)
Affinity DataIC50:  0.200nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221601(US9303045, 88 | US9695195, 88)
Affinity DataIC50:  0.220nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221592(US9303045, 127 | US9303045, 79 | US9695195, 127)
Affinity DataIC50:  0.220nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221622(US9303045, 113 | US9695195, 113)
Affinity DataIC50:  0.230nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221572(US9303045, 58 | US9695195, 58)
Affinity DataIC50:  0.240nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221624(US9303045, 117 | US9303045, 123 | US9695195, 123)
Affinity DataIC50:  0.280nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221610(US9303045, 99 | US9695195, 99)
Affinity DataIC50:  0.290nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221654(US9303045, 159 | US9695195, 159)
Affinity DataIC50:  0.300nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221651(US9303045, 154 | US9695195, 154)
Affinity DataIC50:  0.330nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221561(US9303045, 47 | US9695195, 47)
Affinity DataIC50:  0.330nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221624(US9303045, 117 | US9303045, 123 | US9695195, 123)
Affinity DataIC50:  0.390nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221627(US9303045, 120 | US9695195, 120)
Affinity DataIC50:  0.390nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221648(US9303045, 147 | US9695195, 147)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221535(US9303045, 20 | US9695195, 20)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221622(US9303045, 113 | US9695195, 113)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221626(US9303045, 119 | US9695195, 148)
Affinity DataIC50:  0.400nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221592(US9303045, 127 | US9303045, 79 | US9695195, 127)
Affinity DataIC50:  0.410nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221587(US9303045, 74 | US9695195, 74)
Affinity DataIC50:  0.420nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221644(US9303045, 143 | US9695195, 143)
Affinity DataIC50:  0.420nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221574(US9303045, 60 | US9695195, 60)
Affinity DataIC50:  0.440nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221527(US9303045, 12 | US9695195, 12)
Affinity DataIC50:  0.450nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221677(US9303045, 189 | US9695195, 189)
Affinity DataIC50:  0.460nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221577(US9303045, 63 | US9695195, 63)
Affinity DataIC50:  0.490nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221523(US9303045, 7 | US9695195, 7)
Affinity DataIC50:  0.490nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221550(US9303045, 36 | US9695195, 36)
Affinity DataIC50:  0.5nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221530(US9303045, 15 | US9695195, 15)
Affinity DataIC50:  0.530nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221570(US9303045, 56 | US9695195, 56)
Affinity DataIC50:  0.530nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221524(US9303045, 112 | US9303045, 8 | US9695195, 112)
Affinity DataIC50:  0.530nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221540(US9303045, 26 | US9695195, 26)
Affinity DataIC50:  0.540nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221549(US9303045, 35 | US9695195, 35)
Affinity DataIC50:  0.540nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221633(US9303045, 129 | US9303045, 130 | US9695195, 130)
Affinity DataIC50:  0.550nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221526(US9303045, 10 | US9303045, 111 | US9695195, 111)
Affinity DataIC50:  0.570nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221560(US9303045, 46 | US9695195, 46)
Affinity DataIC50:  0.590nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM98817(US9695195, 51)
Affinity DataIC50:  0.600nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221662(US9303045, 169 | US9695195, 169)
Affinity DataIC50:  0.600nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221645(US9303045, 144 | US9695195, 144)
Affinity DataIC50:  0.610nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221633(US9303045, 129 | US9303045, 130 | US9695195, 130)
Affinity DataIC50:  0.640nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221602(US9303045, 89 | US9695195, 89)
Affinity DataIC50:  0.660nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221641(US9303045, 137 | US9695195, 137)
Affinity DataIC50:  0.680nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221630(US9303045, 126 | US9695195, 126)
Affinity DataIC50:  0.680nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221647(US9303045, 146 | US9695195, 146)
Affinity DataIC50:  0.700nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221548(US9303045, 34 | US9695195, 34)
Affinity DataIC50:  0.740nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221603(US9303045, 90 | US9695195, 90)
Affinity DataIC50:  0.75nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221576(US9303045, 62 | US9695195, 62)
Affinity DataIC50:  0.75nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221678(US9303045, 190 | US9695195, 190)
Affinity DataIC50:  0.75nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221655(US9303045, 160 | US9695195, 160)
Affinity DataIC50:  0.75nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221526(US9303045, 10 | US9303045, 111 | US9695195, 111)
Affinity DataIC50:  0.770nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
Target5-hydroxytryptamine receptor 3A(Homo sapiens (Human))
Takeda Pharmaceutical

US Patent
LigandPNGBDBM221554(US9303045, 40 | US9695195, 40)
Affinity DataIC50:  0.780nMT: 2°CAssay Description:The 5HT3 antagonist activity of the compounds of the invention was determined by measuring the ability of the compounds to inhibit the calcium flux a...More data for this Ligand-Target Pair
Ligand InfoKEGGPC cidPC sid
In DepthDetails US Patent
Displayed 1 to 50 (of 162 total ) | Next | Last >>
Jump to: